Recent News

• 04.15.2025 - Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones
• 04.04.2025 - Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.31.2025 - Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference
• 03.03.2025 - Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
• 02.28.2025 - Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.05.2025 - Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Recent Filings

• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.31.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
• 03.31.2025 - 8-K Current report
• 03.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities